Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE AND ETHINYL ESTRADIOL versus STILPHOSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE AND ETHINYL ESTRADIOL versus STILPHOSTROL.
DROSPIRENONE AND ETHINYL ESTRADIOL vs STILPHOSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drospirenone is a spironolactone analogue with anti-mineralocorticoid and anti-androgenic activity. It suppresses gonadotropin secretion, inhibiting ovulation. Ethinyl estradiol provides negative feedback on LH and FSH, preventing follicular development and ovulation.
Synthetic nonsteroidal estrogen; binds to estrogen receptors, inducing tumor regression in hormone-sensitive cancers.
One tablet (drospirenone 3 mg/ethinyl estradiol 0.02 mg or 0.03 mg) orally once daily for 21 days followed by 7 days of placebo, or 24 active tablets followed by 4 placebo tablets depending on formulation.
0.5-1 mg/kg intravenously daily for 5 days, then 0.5 mg/kg intramuscularly weekly.
None Documented
None Documented
Drospirenone: approximately 30-35 hours (terminal), allowing once-daily dosing. Ethinyl estradiol: approximately 13-20 hours (terminal), supporting daily administration.
Terminal elimination half-life: 50-60 hours (range 40-80 hr) due to enterohepatic recirculation; clinical context: steady-state achieved in ~10-14 days
Drospirenone: ~40-50% renal (as glucuronide conjugates), ~50-60% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal, primarily as glucuronide and sulfate conjugates.
Renal (primarily as glucuronide conjugates, 70-80%); fecal (biliary excretion of conjugates, 20-30%); <5% unchanged
Category D/X
Category C
Estrogen
Estrogen